Asset Management One
ANIP icon

Asset Management One’s ANI Pharmaceuticals ANIP Stock Holding History

Asset Management One’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-9,093
Closed -$359K – 1333
2015
Q3 		$359K Buy
+9,093
New +$517K 0.01% 1128

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Asset Management One's ANIP Position: Q4 2015 in Review

Asset Management One sold out of ANI Pharmaceuticals (ANIP) in Q4 2015, closing a stake of 9,093 shares — an estimated $359K sold.

Asset Management One first reported a position in ANIP in Q3 2015 and held it in 1 quarter. The position peaked at $359K in Q3 2015. 123 funds tracked by Wall St. Rank hold ANIP as of Q4 2015.

  • Asset Management One reported no remaining ANI Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Asset Management One sold 9,093 ANI Pharmaceuticals shares in Q4 2015, an estimated $359K.
  • Asset Management One first reported a position in ANI Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Asset Management One's ANI Pharmaceuticals position peaked at $359K in Q3 2015.
  • 123 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2015.

Based on Asset Management One's 13F filing for Q4 2015, filed 28 Jan 2016.